Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Nephrology
•
Glomerulonephritis
What is your approach to the management of secondary membranous nephropathy with nephrotic range proteinuria?
Related Questions
What is your treatment approach when managing patients with relapsing lupus nephritis who previously achieved remission with mycophenolate and steroids?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
How do you approach the management of patients with suspected membranous lupus nephritis who are found to have positive PLA2R antibodies?
Do you recommend initiating immunosuppression and plasmapheresis in patients with dialysis dependent AKI in the setting of anti-GBM disease who do not have pulmonary involvement?
What is your approach to the use of immunosuppression for patients with poststreptococcal glomerulonephritis?
Do you take any special treatment considerations for elderly patients diagnosed with collapsing FSGS?
How long do you continue maintenance immunosuppression in a patient with PR3 ANCA glomerulonephritis with pulmonary involvement?
Do you use delayed-release budesonide over prednisone or methylprednisolone for the treatment of IgA nephropathy, considering the available safety and efficacy data?
Do you prefer starting a SGLT2i before steroids in patients with IgA nephropathy and proteinuria > 1.0 gram/day who are unable to tolerate ACEi/ARB due to hypotension?
What is your approach to immunosuppressive treatment for patients with crescentic IgA vasculitis and kidney manifestations?
